Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.44 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.44 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.44 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.44 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.44 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.44 |
| ▸ | GSR | P00390 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.41 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.41 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.41 |
| ▸ | NPY4R | P50391 | 5/20 | 0.41 |
| ▸ | NPY1R | P25929 | 4/20 | 0.41 |
| ▸ | NPY2R | P49146 | 3/20 | 0.41 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.40 |
| ▸ | NMT2 | O60551 | 1/20 | 0.40 |
| ▸ | NMT1 | P30419 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6535292 | 1.00 | EGFR (0.46) | EGFRDPP8DPP9DPP7GNAI3 | |
| SCHEMBL6535211 | 0.99 | EGFR (0.47) | EGFRDPP8DPP9DPP7GNAI3 | |
| SCHEMBL6534929 | 0.99 | EGFR (0.47) | EGFRDPP8DPP9DPP7GNAI3 | |
| SCHEMBL6534934 | 0.99 | EGFR (0.47) | EGFRDPP8DPP9DPP7GNAI3 | |
| SCHEMBL6535206 | 0.99 | EGFR (0.47) | EGFRDPP8DPP9DPP7GNAI3 | |
| SCHEMBL30537471 | 0.95 | EGFR (0.43) | EGFRDPP8DPP9DPP7GNAI3 | |
| SCHEMBL30537469 | 0.92 | EGFR (0.47) | EGFRDPP8DPP9DPP7OPRK1 | |
| SCHEMBL29591854 | 0.91 | EGFR (0.52) | EGFRDPP8DPP9DPP7GNAI3 | |
| SCHEMBL29714789 | 0.90 | ERAP2 (0.48) | EGFRDPP8DPP9DPP7GSR | |
| SCHEMBL6534852 | 0.88 | TERT (0.45) | DPP8DPP9DPP7GNAI3GNAO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111602822-B | Liver fat synthesis inhibitor | 不二制油集团控股株式会社 | 2024-10-01 | — | — | CN | disclosed |
| CN-111602822-B | Liver fat synthesis inhibitor | 不二制油集团控股株式会社 | 2024-10-01 | — | — | CN | disclosed |
| US-20230109312-A1 | NOVEL LINKERS FOR ANTIBODY-DRUG CONJUGATES AND RELATED COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | IGENICA BIOTHERAPEUTICS, INC. | 2023-04-06 | — | — | US | disclosed |
| US-11229711-B2 | Linkers for antibody-drug conjugates and related compounds, compositions, and methods of use | Magenta Therapeutics, Inc. (US) | 2022-01-25 | — | — | US | disclosed |
| EP-1015482-A4 | ISOLATED CANDIDA ALBICANS OLIGOPEPTIDE TRANSPORTER GENE | UNIV TENNESSEE RES CORP (US) | 2004-09-15 | — | — | EP | disclosed |
| US-6441134-B1 | OLIGOPEPTIDE MEMBRANE TRANSPORTER WHICH IS NOT A MEMBER OF THE PEPTIDE TRANSPORT (PTR) OR ATP BINDING CASSETTE (ABC) FAMILIES; USE TARGETING ANTICANDIDAL (FUNGICIDAL) DRUGS | THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION | 2002-08-27 | — | — | US | disclosed |
| EP-1015482-A1 | ISOLATED CANDIDA ALBICANS OLIGOPEPTIDE TRANSPORTER GENE | THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION (US) | 2000-07-05 | — | — | EP | disclosed |
| WO-1998034950-A1 | ISOLATED CANDIDA ALBICANS OLIGOPEPTIDE TRANSPORTER GENE | THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION (US) | 1998-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230109312-A1 | NOVEL LINKERS FOR ANTIBODY-DRUG CONJUGATES AND RELATED COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | SDCBP, DCLRE1A, BCR | EGFR 289/4885DPP8 2642/4885DPP9 2681/4885 |
| US-11229711-B2 | Linkers for antibody-drug conjugates and related compounds, compositions, and methods of use | CLSPN, SDCBP, DCLRE1A | EGFR 339/4885DPP8 2683/4885DPP9 2688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.